ArcticZymes Technologies ASA (OSL:AZT)

Norway flag Norway · Delayed Price · Currency is NOK
21.50
+0.40 (1.90%)
At close: Mar 13, 2026
Market Cap1.10B +18.0%
Revenue (ttm)118.21M +9.3%
Net Income9.88M +16.7%
EPS0.19 +14.3%
Shares Out51.07M
PE Ratio113.16
Forward PE52.50
Dividendn/a
Ex-Dividend Daten/a
Volume22,148
Average Volume31,605
Open21.20
Previous Close21.10
Day's Range20.90 - 21.60
52-Week Range14.00 - 31.40
Beta0.39
RSI42.86
Earnings DateApr 30, 2026

About OSL:AZT

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1990
Employees 53
Stock Exchange Oslo Børs
Ticker Symbol AZT
Full Company Profile

Financial Performance

In 2025, OSL:AZT's revenue was 118.21 million, an increase of 9.34% compared to the previous year's 108.11 million. Earnings were 9.88 million, an increase of 16.66%.

Financial Statements